Drug Profile
Research programme: antibody therapeutics - ABL Bio
Alternative Names: ABL101-108; TRIA001; TRIA002; TRIO2-01Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator ABL Bio
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Checkpoint kinase inhibitors; Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in South Korea (Parenteral)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (Parenteral)
- 25 Mar 2019 TRIGR Therapeutics plans clinical trial for TRIO2 01, TRIA 001 and TRIA 002 in Cancer by mid-2021